Genenta Science S.p.A (GNTA) Receivables - Other (2021 - 2022)
Genenta Science S.p.A (GNTA) posted Receivables - Other of $41982.2 for Q4 2022, up 11.14% sequentially from $37774.9 in Q2 2022, and down 36.74% YoY from $66360.6 in Q4 2021.
Genenta Science S.p.A (GNTA) Receivables - Other (2021 - 2022) Analysis & Trends
Genenta Science S.p.A has reported Receivables - Other for 2 years, with the latest figure at $41982.2 in Q4 2022.
- Quarterly Receivables - Other fell 36.74% year-over-year to $41982.2 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $41982.2 (down 36.74% YoY) and the FY2022 annual result came in at $41982.2, down 36.74% from the prior year.
- Receivables - Other improved to $41982.2 in Q4 2022 per GNTA's latest filing, from $37774.9 in the prior quarter.
- Over five years, Receivables - Other peaked at $66360.6 in Q4 2021 and troughed at $37774.9 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Genenta Science S.p.A | 23.36 Mn | -35.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 41,982.16 |
| Dec 31, 2022 | 41,982.16 |
| Jun 30, 2022 | 37,774.87 |
| Jun 30, 2022 | 37,774.87 |
| Dec 31, 2021 | 66,360.61 |
| Dec 31, 2021 | 66,360.61 |